NTLA compared with ARCT: revenue, margins and what each company keeps, and the suppliers and customers both name

NTLAIntellia Therapeutics, Inc.

Mkt capRevenueRevenue

ARCTArcturus Therapeutics Holdings Inc.

Mkt capRevenueRevenue

Compare

NTLAIntellia Therapeutics, Inc.

ARCTArcturus Therapeutics Holdings Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only NTLA 4

REGNRegeneron Pharmaceuticalscustomer

CRBUCaribou Biosciencessupplier

—AvenCell Therapeuticsunlistedcustomer

—SparingVision SASunlistedcustomer

Shared 0

No shared counterparties.

Only ARCT 3

—Biomedical Advanced Research and Development Authority (BARDA)unlistedcustomer

—CSL Seqirusunlistedcustomer

—Meiji Seika Pharmaunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

NTLAIntellia Therapeutics, Inc.

12.03▲+3.17%

Mkt cap$1.6BRevenue$8MQ2 FY26Revenue$68MFY25

ARCTArcturus Therapeutics Holdings Inc.

9.24▼−2.64%

Regular sessionNov 3 '26

Mkt cap$269.7MRevenue$3MQ2 FY26Revenue$82MFY25

Compare

Regular sessionNov 3 '26

NTLAIntellia Therapeutics, Inc.

ARCTArcturus Therapeutics Holdings Inc.

12.03▲+3.17%

Price

9.24▼−2.64%

$1.6B

Mkt cap

$269.7M

Q2 FY26$8M

Revenue

$3MQ2 FY26

FY25$68M

Revenue

$82MFY25

NTLA12.03▲+3.17%vsARCT9.24▼−2.64%Regular sessionNov 3 '26